The linked FDA record identifies Sienco, Inc. as applicant on K260909, received March 19, 2026 and decided October 27, 2026 with decision code SESE, meaning substantially equivalent. The submission covers three Sonoclot configurations under product code JPA, regulation 21 CFR 864.5425, in the hematology advisory committee. The filing address is in Boulder, Colorado; that is a correspondence address in the record, not a verified headquarters. The MedtechLedger collection holds one linked 510(k) record, and the single decision in it is SESE. [1][6]

The K260909 submission and its scope

K260909 lists three device names: the Sonoclot Coagulation & Platelet Function Analyzer System with Sonoclot Viewer (SCP1), the same system with Sonoclot Viewer (SCP2), and the Sonoclot Coagulation Analyzer System with Sonoclot Viewer (SC1). The record carries product code JPA, device class 2, regulation number 864.5425, and the openFDA device name "System, Multipurpose For In Vitro Coagulation Studies." The decision description is "Substantially Equivalent," clearance type "Special," and the statement field reads "Summary." [1]

An independent index of the same clearance places K260909 under the Hematology advisory committee, subpart F for automated and semi-automated hematology devices, regulation 21 CFR 864.5425 and product code JPA, attributed to Sienco, Inc. That index adds no product performance data beyond the filing identity. [6]

Documented analyzer configurations

Sienco-published product pages describe three models. The one-channel SC1 Coagulation Analyzer gives ACT and Clot Rate results and may be used with SonoView Data Retrieval Software or stand-alone, with kACT and gbACT kits listed. The one-channel SCP1 Coagulation & Platelet Function Analyzer gives quantitative ACT, Clot Rate and Platelet Function results plus the qualitative Sonoclot Signature, for use with Signature Viewer Data Collection Software, with kACT, gbACT and gbACT+ kits listed. The two-channel SCP2 provides ACT, Clot Rate and Platelet Function results, also for use with Signature Viewer, with the same three kit types listed. [5]

The SCP2 Operator's Manual, revision 3.4, is published under the Sonoclot name and states it is manufactured for Sienco, Inc. at the Boulder, Colorado address, with contact telephone numbers, a sienco.com address and a [email protected] e-mail. The manual notes that Sonoclot is a registered trademark of Sienco, Inc. and that Sonoclot Analyzers are protected under U.S. and foreign patents. It also names QNET BV in Haaren, the Netherlands, in the distributor context. [3]

Earlier clearance and software lineage

A January 4, 2023 FDA letter for K223635 addresses Sienco, Inc. and Jennifer Aiken as Regulatory Compliance Director at the Boulder, Colorado address. That clearance covers the Sonoclot Coagulation & Platelet Function Analyzer System with Sonoclot Viewer under regulation 21 CFR 864.7140, Activated Whole Blood Clotting Time Tests, class II, product code JBP, received December 5, 2022. [4]

The K223635 summary describes Sonoclot Viewer as a reengineered software revision of the previously cleared Signature Viewer program for use with Sonoclot Analyzers, stating the two share intended use and software features. It states that Sonoclot Viewer and Signature Viewer both give a qualitative Sonoclot Signature graph and quantitative results for activated clotting time, rate of fibrin polymerization (Clot Rate) and platelet function information, and that analyzer model DP-2951 is the same model used in K002528. [4]

What the supplied record does and does not establish

The supplied collection contains one linked 510(k) record, K260909, and its decision count is one SESE. That count describes the supplied filings as of the snapshot date; it is not a measure of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]

Ownership, parent companies, customer relationships, certifications, commercial availability and clinical performance are not established by the public documents and remain unknown. The Boulder address appears in FDA correspondence and in Sienco-published manuals as a manufacturing and contact address; the sources do not designate a headquarters. [1][3][4]